CompletedNCT01933880
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
Medication studyAges 7–12China
Understand this study
Who was this study for?
Listed age limits: 7 years to 12 years.
- Listed locations
- Beijing and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 194
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China
- Age range
- From 7 Years to 12 Years
- Official registry ID
- NCT01933880
- Official title
Show the full official title
An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedBeijing · Changchun · Guangzhou
3 more locations
- Hangzhou
- Shanghai
- Shenzhen
Questions about this study
Who is behind this study?
The study sponsor is Xian-Janssen Pharmaceutical Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH).
Who was this study for?
Listed age limits: 7 years to 12 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me